1. Joint Committee on Vaccination and Immunisation. JCVI statement on COVID-19 vaccination of children and young people aged 12 to 17 years (accessed 3rd October 2021).
Google Scholar2. Gov.uk. The Medicines and Healthcare Products Regulatory Agency concludes positive safety profile for Pfizer/BioNTech vaccine in 12- to 15-year-olds. 2021. https://www.gov.uk/government/news/the-mhra-concludes-positive-safety-profile-for-pfizerbiontech-vaccine-in-12-to-15-year-olds (accessed 3rd October 2021).
Google Scholar3. Gov.uk. Independent report: JCVI statement on COVID-19 vaccination of children and young people aged 12 to 17 years: 4 August 2021. https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-4-august-2021 (accessed 3rd October 2021).
Google Scholar4. Gov.uk. Independent report: JCVI statement on COVID-19 vaccination of children aged 12 to 15 years: 3 September 2021. https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-vaccination-of-children-aged-12-to-15-years (accessed 3rd October 2021).
Google Scholar5. Office for National Statistics. Technical article: Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021.
Google Scholar6. Stephenson T, Shafran R, De Stavola B, et al. Long COVID and the mental and physical health of children and young people: national matched cohort study protocol (the CLoCk study). BMJ Open 2021; 11: e052838.
Google Scholar7. Radtke T, Ulyte A, Puhan MA and Kriemler S. Long-term symptoms after SARS-CoV-2 infection in children and adolescents. JAMA 2021; 326: 869–871.
Google Scholar8. Miller M, Nguyen V, Navaratnam AM, Shrotri M, Kovar J, Hayward AC, et al. Prevalence of persistent symptoms in children during the COVID-19 pandemic: evidence from a household cohort study in England and Wales. MedRxiv. 2021.
Google Scholar9. Ministry of Health, Israel. A New Survey. See https://www.gov.il/he/departments/news/childrenpostcoronaeffects (last accessed 28 September 2021).
Google Scholar10. Molteni ESC, Canas LS, Bhopal SS, Huges RC and Antonelli M. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health 2021; 5: 708–718.
Google Scholar11. Gov.uk. Correspondence: key published inputs to the UK CMOs advice on universal vaccination of children and young people aged 12 to 15 years against COVID-19. https://www.gov.uk/government/publications/universal-vaccination-of-children-and-young-people-aged-12-to-15-years-against-covid-19 (Last accessed 3rd October 2021).
Google Scholar12. European Medicines Agency. COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU. 2021.
Google Scholar13. Pitchers C. Pfizer’s COVID jab is first in EU to be approved for 12-15 year olds. Euronews 2021. https://www.euronews.com/2021/05/28/ema-approves-pfizer-jab-for-use-on-12-15-year-olds (Accessed 3rd October 2021).
Google Scholar14. Centers for Disease Control and Prevention. Demographic Characteristics of People Receiving COVID-19 Vaccinations in the United States. USA: Centers for Disease Control and Prevention, 2021.
Google Scholar15. Reed J. Covid: which countries are vaccinating children and why? BBC News. See https://www.bbc.co.uk/news/health-58516207 (2021, last accessed 28 September 2021).
Google Scholar16. Centers for Disease Control and Prevention. COVID-19 Vaccines for Children and Teens, 2021.
Google Scholar17. Wallace M and Oliver S. COVID-19 mRNA Vaccines in Adolescents and Young adults: Benefit-risk Discussion. USA: Centers for Disease Control, 2021.
Google Scholar18. Bozkurt, B, Kamat, I, Hotez, PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation 2021; 144: 471–484.
Google Scholar | Crossref | Medline19. Gargano, JW, Wallace, M, Hadler, SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 977–982.
Google Scholar | Crossref | Medline20. Shimabukuro T. Advisory Committee on Immunization Practices (ACIP). COVID-19 Vaccine safety updates. 23rd June 2021.
Google Scholar21. U.S. Department of Health and Human Services. Statement Following Centers for Disease Control ACIP Meeting from Nation’s Leading Doctors, Nurses, Pharmacists and Public Health Leaders on Benefits of Vaccination. 2021.
Google Scholar22. Jain SS, Steele JM, Fonseca B, et al. COVID-19 vaccination-associated myocarditis in adolescents. Pediatrics 2021. e2021053427; DOI: https://doi.org/10.1542/peds.2021-053427A.
Google Scholar23. Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine – weekly summary of Yellow Card reporting. 30 July 2021.
Google Scholar24. Boehmer, TK, Kompaniyets, L, Lavery, AM, Hsu, J, Ko, JY, Yusuf, H, et al. Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data – United States, March 2020–January 2021. Morbidity Mortality Weekly Rep (MMWR) 2021; 70: 1228–1232.
Google Scholar | Crossref | Medline25. Singer ME, Taub IB, Kaelber DC. Risk of myocarditis from COVID-19 infection in people under 20: a population-based analysis. MedRxiv. 2021. DOI: 10.1101/2021.07.23.21260998.
Google Scholar26. Barda, N, Dagan, N, Ben-Shlomo, Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med 2021; 385: 1078–1090.
Google Scholar | Crossref | Medline27. Nalbandian, A, Sehgal, K, Gupta, A, et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601–615.
Google Scholar | Crossref | Medline28. Ray, STJ, Abdel-Mannan, O, Sa, M, et al. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. Lancet Child Adolesc Health 2021; 5: 631–641.
Google Scholar | Crossref | Medline29. Douaud GLS, Alfaro-Almagro F, Arthofer C, Wang C, Lange F, Andersson JLR, et al. Brain imaging before and after COVID-19 in UK Biobank. MedRxiv 2021. doi: https://doi.org/10.1101/2021.06.11.21258690.
Google Scholar30. Public Health England. Weekly national Influenza and COVID-19 surveillance report: week 36 report. 9 September 2021.
Google Scholar31. Public Health England. Hospitalisations by age, England. See https://t.co/UC9VXodKXG?amp=1 (last checked 28 September 2021).
Google Scholar32. Public Health England. COVID-19 Health Inequalities Monitoring for England (CHIME) tool. See https://analytics.phe.gov.uk/apps/chime/ (last checked 28 September 2021).
Google Scholar33. SAGE. Ninety-fifth SAGE meeting on COVID-19. See https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1017296/S1360_SAGE_95_minutes.pdf (last checked 28 September 2021).
Google Scholar34. Gov.uk. Coronavirus (COVID-19) in the UK. Cases in England. See https://coronavirus.data.gov.uk/details/cases?areaType=nation&areaName=England (last checked 28 September 2021).
Google Scholar35. Clews ML. Covid ‘surge' likely when schools return, expert warns. Times Educational Supplement 2021. August 2021 https://www.tes.com/news/covid-surge-schools-pandemic-vaccine-young-nhs (Last accessed 3rd October 2021).
Google Scholar36. Wood A, Denholm R, Hollings S, et al. Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: data resource. BMJ 2021; 373: n826.
Google Scholar37. Ministry of Health Israel. Explanation about the Effectiveness of the Vaccine for Coronavirus in Israel. Israel: Ministry of Health Israel, 2021.
Google Scholar38. REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021. 2021.
Google Scholar39. Office for National Statistics. Coronavirus (COVID-19) latest insights: Vaccines 16 September 2021.
Google Scholar40. Public Health Scotland. Daily Case Trends By Age and Sex. See https://www.opendata.nhs.scot/dataset/covid-19-in-scotland/resource/9393bd66-5012-4f01-9bc5-e7a10accacf4 (last checked 28 September 2021).
Google Scholar41. Swann, OV, Holden, KA, Turtle, L, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ 2020; 370: m3249–m3249.
Google Scholar | Crossref | Medline42. Penner, J, Abdel-Mannan, O, Grant, K, et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study. Lancet Child Adolesc Health 2021; 5: 473–482.
Google Scholar | Crossref | Medline43. Toraih, EA, Hussein, MH, Elshazli, RM, et al. Multisystem inflammatory syndrome in pediatric COVID-19 patients: a meta-analysis. World J Pediatr 2021; 17: 141–151.
Google Scholar | Crossref | Medline44. Gov.uk. International Severe Acute Respiratory and Emerging Infection Consortium: supplementary Information - comparison of children and young people admitted with SARS-CoV-2 across the UK in the first and second pandemic waves, 9 September 2021. https://www.gov.uk/government/publications/isaric-supplementary-information-comparison-of-children-and-young-people-admitted-with-sars-cov-2-across-the-uk-in-the-first-and-second-pandemic-wa (Last accessed 3rd October 2021).
Google Scholar45. Public Health England. Risk assessment for SARS-CoV-2 variant Delta: 23 July 2021, 2021.
Google Scholar46. Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefings, 15–17 2021.
Google Scholar47. Delahoy, MJ, Ujamaa, D, Whitaker, M, O’Halloran, A, Anglin, O, Burne, E, et al. Hospitalizations associated with COVID-19 among children and adolescents – COVID-NET, 14 States, March 1, 2020–August 14, 2021. Morb Mortality Weekly Rep 2021; 70: 1255–1260.
Google Scholar | Crossref | Medline48. Lopez Bernal, J, Andrews, N, Gower, C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 2021; 385: 585–594.
Google Scholar | Crossref | Medline49. Rella SA, Kulikova YA, Dermitzakis ET and Kondrashov FA. Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains. Scientific Reports 2021; 11: 15729.
Google Scholar50. Gog JR, Hill EM, Danon L and Thompson RN. Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple model. The Royal Society. See https://doi.org/10.1098/rsos.210530 (last checked 28 September 2021).
Google Scholar51. Hillis, SD, Unwin, HJT, Chen, Y, et al. Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study. Lancet 2021; 398: 391–402.
Google Scholar | Crossref | Medline52. Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. London: Office for National Statistics, 2021.
Google Scholar53. Gurdasani D, Alwan NA, Greenhalgh T, et al. School reopening without robust COVID-19 mitigation risks accelerating the pandemic. Lancet 2021; 397: 1177–1178.
Google Scholar54. Centers for Disease Control and Prevention. Interim Public Health Recommendations for Fully Vaccinated People. USA: Centers for Disease Control, 2021.
Google Scholar55. World Health Organisation. COVID-19 Virtual Press conference transcript - 25 June 2021. Geneva: WHO, 2021.
Google Scholar